# FGFR2 fusions and rearrangements

Source: https://onco.cc/terms/fgfr2-fusion/  
OnCo record `fgfr2-fusion` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A broken-and-rejoined FGFR2 gene that drives about one in eight intrahepatic bile duct cancers and can be switched off with pills.

## Summary

Detected by RNA or DNA sequencing; partners are diverse (BICC1 most common). Pemigatinib (ORR 37%) and futibatinib (ORR 42%) are approved; acquired resistance arises through FGFR2 kinase-domain mutations (N550, V565 gatekeeper) that next-generation inhibitors (tinengotinib, RLY-4008 lirafugratinib) target. Hyperphosphataemia is the class effect.

## Fields

- Kind: Term
- Last checked: 2026-09-07

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Fibroblast_growth_factor_receptor_2
- FIGHT-202: pemigatinib for previously treated FGFR2-rearranged cholangiocarcinoma (Lancet Oncology 2020): https://doi.org/10.1016/S1470-2045(20)30109-1

## Connected records

- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Intrahepatic cholangiocarcinoma](https://onco.cc/cancers/intrahepatic-cholangiocarcinoma/)
- targets: [FGFR2](https://onco.cc/targets/fgfr2/)
- drugs: [Futibatinib](https://onco.cc/drugs/futibatinib/), [Pemigatinib](https://onco.cc/drugs/pemigatinib/), [Tinengotinib](https://onco.cc/drugs/tinengotinib/)
- terms: [Gene fusion](https://onco.cc/terms/gene-fusion/)
- ideas: [ctDNA-guided switching among FGFR inhibitors](https://onco.cc/ideas/idea-btc-ctdna-fgfr-resistance/)
- biomarkers: [FGFR2 fusion or rearrangement](https://onco.cc/biomarkers/fgfr2-fusion-rearrangement/)

---
JSON: https://onco.cc/api/v1/entities/fgfr2-fusion.json